Phathom Pharmaceuticals, Inc.

NasdaqGS PHAT

Phathom Pharmaceuticals, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 17.67

Phathom Pharmaceuticals, Inc. Price to Sales Ratio (P/S) is 17.67 on January 14, 2025, a -97.35% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Phathom Pharmaceuticals, Inc. 52-week high Price to Sales Ratio (P/S) is 982.16 on March 27, 2024, which is 5,457.26% above the current Price to Sales Ratio (P/S).
Phathom Pharmaceuticals, Inc. 52-week low Price to Sales Ratio (P/S) is 17.23 on January 13, 2025, which is -2.50% below the current Price to Sales Ratio (P/S).
Phathom Pharmaceuticals, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 247.87.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: PHAT

Phathom Pharmaceuticals, Inc.

CEO	Ms. Terrie J. Curran
IPO Date	Oct. 25, 2019
Location	United States
Headquarters	100 Campus Drive
Employees	452
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Key trends

Past 5 years